Leukemia, Lymphocytic, Chronic Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Leukemia, Lymphocytic, Chronic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting

Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia

Leukemia, Lymphocytic, Chronic, B-Cell
Janssen Cilag S.A.S.180 enrolled1 locationNCT06299540
Recruiting
Phase 2

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

Small Lymphocytic LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC320 enrolled73 locationsNCT05963074
Recruiting
Phase 3

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

CLLLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Small Lymphocytic+3 more
Merck Sharp & Dohme LLC735 enrolled52 locationsNCT05947851
Recruiting
Phase 1Phase 2

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Small Lymphocytic
Juno Therapeutics, a Subsidiary of Celgene320 enrolled86 locationsNCT03331198
Recruiting
Phase 1Phase 2

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Acute Lymphoblastic LeukemiaSmall Lymphocytic LymphomaLymphoblastic Lymphoma+4 more
National Cancer Institute (NCI)132 enrolled1 locationNCT06364423
Recruiting
Phase 2

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

Lymphoma, Non-HodgkinB-cell LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Eli Lilly and Company13 enrolled6 locationsNCT07162181
Recruiting

Family Study of Lymphoproliferative Disorders

Multiple MyelomaLymphoma, Non-HodgkinLymphoma, B-Cell+2 more
Mayo Clinic3,000 enrolled1 locationNCT00626496
Recruiting

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

Lymphoproliferative DisordersNon-Hodgkin's LymphomaHodgkin's Disease+1 more
Dana-Farber Cancer Institute1,500 enrolled1 locationNCT00131014
Recruiting

Institut Paoli Calmettes Chronic Lymphatic Leukemia Database

Leukemia, Lymphocytic, Chronic, B-Cell
Institut Paoli-Calmettes4,200 enrolled1 locationNCT02869529